[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543583":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":29,"locations":37,"responsibleParty":144,"collaborators":10,"id":146,"slug":10,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":10,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":10,"maxAge":10,"enrollmentInfo":153,"targetDuration":10,"studyType":156,"phases":10,"briefSummary":157,"conditions":158,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants treated with idecabtagene vicleucel",null,[12],"Biological: Idecabtagene vicleucel",{"label":14,"type":10,"description":10,"interventionNames":15},"Participants treated with lisocabtagene maraleucel",[16],"Biological: Lisocabtagene maraleucel",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BIOLOGICAL","Idecabtagene vicleucel","As per product label",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":10},"Lisocabtagene maraleucel",[14],[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":36,"role":32,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[38,54,69,82,93,107,121,130],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Local Institution - 0016","NOT_YET_RECRUITING","Portland","Oregon","97239-3098","United States",{"type":46,"coordinates":47},"Point",[48,49],-122.67621,45.52345,{"lat":49,"lon":48},[52],{"name":53,"role":32,"phone":10,"phoneExt":10,"email":10},"Site 0016",{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":44,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Ut Southwestern","RECRUITING","Dallas","Texas","75235",{"type":46,"coordinates":61},[62,63],-96.80667,32.78306,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":68,"phoneExt":10,"email":10},"Larry Anderson, Site 0008","214-648-5906",{"facility":70,"status":56,"city":71,"state":72,"zip":73,"country":44,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Huntsman Cancer Institute at the University of Utah","Salt Lake City","Utah","84112",{"type":46,"coordinates":75},[76,77],-111.89105,40.76078,{"lat":77,"lon":76},[80],{"name":81,"role":32,"phone":10,"phoneExt":10,"email":10},"Lauren Lee, Site 0010",{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":44,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"Local Institution - 0004","WITHDRAWN","Madison","Wisconsin","53792",{"type":46,"coordinates":89},[90,91],-89.40123,43.07305,{"lat":91,"lon":90},{"facility":94,"status":56,"city":95,"state":10,"zip":96,"country":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Universitaetsklinikum Essen (AoR)","Essen","45147","Germany",{"type":46,"coordinates":99},[100,101],7.01228,51.45657,{"lat":101,"lon":100},[104],{"name":105,"role":32,"phone":106,"phoneExt":10,"email":10},"Bastian von Tresckow, Site 0001","+491631751277",{"facility":108,"status":56,"city":109,"state":110,"zip":111,"country":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Toyokawa City Hospital","Toyokawa","Aichi-ken","442-8561","Japan",{"type":46,"coordinates":114},[115,116],137.4,34.81667,{"lat":116,"lon":115},[119],{"name":120,"role":32,"phone":10,"phoneExt":10,"email":10},"Akimi Kawai, Site 0012",{"facility":122,"status":84,"city":123,"state":123,"zip":124,"country":112,"cosmosGeoPoint":125,"geoPoint":129,"contacts":10},"Local Institution - 0003","Kumamoto","8608556",{"type":46,"coordinates":126},[127,128],130.69181,32.80589,{"lat":128,"lon":127},{"facility":131,"status":56,"city":132,"state":10,"zip":133,"country":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Kantonsspital Aarau","Aarau","5001","Switzerland",{"type":46,"coordinates":136},[137,138],8.04422,47.39254,{"lat":138,"lon":137},[141],{"name":142,"role":32,"phone":143,"phoneExt":10,"email":10},"Sabine Veronika Gerull, Site 0002","+41628386505",{"type":145,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100543583",false,"NCT06357754","Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy","Protocol for Transgene Assay Service","Inclusion Criteria:\n\n* Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.\n* Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.\n\nExclusion Criteria:\n\n* Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.\n* Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.","ALL",{"count":154,"type":155},50,"ESTIMATED","OBSERVATIONAL","The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.",[159,160,161],"Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukaemia","Multiple Myeloma","2026-01-21",{"date":164,"type":165},"2026-01-22","ACTUAL",{"date":167,"type":165},"2023-10-06",{"date":169,"type":155},"2038-10-06",{"name":5,"class":6},8]